Group 1 - Company Anning Co., Ltd. reported third-quarter performance, with revenue for the first three quarters of 2025 approximately 1.607 billion yuan, an increase of 18.19% year-on-year [1] - The net profit attributable to shareholders of the listed company was approximately 633 million yuan, a decrease of 7.28% year-on-year [1] - Basic earnings per share were 1.3432 yuan, reflecting a year-on-year decrease of 21.3% [1] Group 2 - As of the report, Anning Co., Ltd. has a market capitalization of 15.1 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2] - The secondary market for biomedicine is thriving, while the primary market is experiencing a cooling in fundraising [2]
安宁股份:2025年前三季度净利润约6.33亿元